Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18088735 | 0.85 | TP53 (0.43) | — | |
| SCHEMBL22002781 | 0.82 | ESR2 (0.37) | — | |
| SCHEMBL22002799 | 0.82 | KIF11 (0.44) | DRD2DRD3 | |
| SCHEMBL22002787 | 0.77 | RAB9A (0.43) | — | |
| SCHEMBL9170915 | 0.76 | TP53 (0.48) | — | |
| SCHEMBL6324914 | 0.76 | HTR2A (0.62) | CHRNB4CHRNA3HTR2AHTR2CHTR2B | |
| SCHEMBL22003029 | 0.75 | TBXA2R (0.44) | — | |
| SCHEMBL22002783 | 0.75 | HSD11B1 (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL22003023 | 0.74 | MEN1 (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL22003033 | 0.74 | MEN1 (0.37) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654788-B2 | Method for synthesizing novel compounds derived from 3-hydroxy-cyclopentyl acetic acid | L'OREAL (FR) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654788-B2 | Method for synthesizing novel compounds derived from 3-hydroxy-cyclopentyl acetic acid | HSD17B12, FASN, AKR1C3 | DRD2 1391/4885CHRNB4 2896/4885CHRNA3 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.